Literature DB >> 10611081

Regulation of angiotensin II production and angiotensin receptors in microvascular endothelial cells from bovine corpus luteum.

K Hayashi1, A Miyamoto, B Berisha, M R Kosmann, K Okuda, D Schams.   

Abstract

Recent findings suggest that the ovarian renin-angiotensin system regulates ovarian function through the paracrine/autocrine actions of angiotensin (Ang) II. The aims of this study were to investigate 1) the endothelial cell capacity to convert Ang I to Ang II, 2) the effects of endocrine and paracrine/autocrine factors on Ang II production in microvascular endothelial cells (MVE) derived from the developing corpora lutea (CL), and 3) the relationship between Ang II peptide concentration and expression of mRNA for angiotensin type 1 and 2 receptors (ATR1 and AT2R) in the bovine CL at different stages of the estrous cycle. When Ang I was added to the MVE at a concentration of 10(-9) M, it was converted to Ang II (21%). The production of Ang II from Ang I time-dependently rose for 24 h. Addition of captopril (an inhibitor of Ang-converting enzyme [ACE]) to the MVE cultures significantly inhibited Ang II production from 6 h to 24 h (P < 0.05). Addition of estradiol-17beta (E(2)) + vascular endothelial growth factor and E(2) + basic fibroblast growth factor to MVE cultures increased Ang II production, whereas E(2) or growth factors alone had no effect. Specific transcription for AT1R and AT2R was detected in bovine CL and MVE. There were no significant changes in Ang II tissue concentration or AT1R mRNA expression using reverse transcription-polymerase chain reaction during the estrous cycle. In contrast, AT2R mRNA expression decreased during the midluteal phase (P < 0.05) and increased to the highest level during the late luteal phase (P < 0.05). Results demonstrated that Ang II is generated from Ang I in MVE isolated from the developing bovine CL, indicating that MVE have ACE activity. In addition, mRNA expression for Ang II receptors was detected in the bovine CL and the luteal MVE. These results suggest that Ang II is produced by actions of the local renin-angiotensin system, at least in part, on MVE in the bovine CL, and that this peptide may be involved in the regulation of luteal function during early development and luteolysis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10611081     DOI: 10.1095/biolreprod62.1.162

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  7 in total

1.  The expression of angiotensin and endothelin system members in bovine corpus luteum during estrous cycle and pregnancy.

Authors:  Bajram Berisha; Dieter Schams; Akio Miyamoto
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

Review 2.  Interaction of SARS-CoV-2 With RAS / ACE2 in the Female Reproductive System.

Authors:  Farideh Zafari Zangeneh
Journal:  J Family Reprod Health       Date:  2022-03

3.  The regulators of VEGF expression in mouse ovaries.

Authors:  So Young Shin; Ho-Jung Lee; Duck-Sung Ko; Hoi-Chang Lee; Won Il Park
Journal:  Yonsei Med J       Date:  2005-10-31       Impact factor: 2.759

4.  Immunocytochemical localization of angiotensin II receptor subtypes 1 and 2 in the porcine fetal, prepubertal and postpubertal ovary.

Authors:  Gail Shuttleworth; Morag G Hunter; Graham Robinson; Fiona Broughton Pipkin
Journal:  J Anat       Date:  2002-09       Impact factor: 2.610

Review 5.  Local Renin-Angiotensin system in the reproductive system.

Authors:  Daniel Herr; Inga Bekes; Christine Wulff
Journal:  Front Endocrinol (Lausanne)       Date:  2013-10-18       Impact factor: 5.555

Review 6.  Microvascular endothelial cells of the corpus luteum.

Authors:  John S Davis; Bo R Rueda; Katherina Spanel-Borowski
Journal:  Reprod Biol Endocrinol       Date:  2003-11-10       Impact factor: 5.211

Review 7.  Role of VEGF in kidney development, microvascular maintenance and pathophysiology of renal disease.

Authors:  Byung-Soo Kim; Michael S Goligorsky
Journal:  Korean J Intern Med       Date:  2003-06       Impact factor: 2.884

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.